Tessera Therapeutics to Present New Data Across Preclinical Programs for its Gene Writing™ and Delivery Platforms at the American Society of Gene and Cell Therapy 27th Annual Meeting SOMERVILLE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Tessera Therapeutics, a biotechnology company pioneering a new approach to genome engineering through the development of its Gene Writing™ and...

Tessera Therapeutics Presents New Data Demonstrating the Potential of Gene Writing™ Technology at the American Society of Gene and Cell Therapy 26th Annual Meeting RNA Gene Writing™ platform demonstrates continued advances in rewriting to correct pathogenic mutations responsible for phenylketonuria (PKU), alpha-1 antitrypsin deficiency (AATD) and sickle cell...

Tessera Therapeutics to Present New Data Showcasing the Broad Potential of its Gene Writing™ and Delivery Platforms at the American Society of Gene and Cell Therapy 26th Annual Meeting SOMERVILLE, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic medicine known as Gene Writing™, today announced that it will...

Tessera Therapeutics Names Cynthia M. Patton as General Counsel and Secretary SOMERVILLE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic medicine known as Gene Writing™, announced the appointment...

Tessera Therapeutics Highlights Advancements Across its Gene Writing™ and Delivery Platforms Including Proof of Concept Data in Non-Human Primates RNA Gene Writing™ platform demonstrates clinically relevant levels of in vivo rewriting in the genome of liver cells of non-human primates following a single administrationRNA Gene Writing™ platform...